| Literature DB >> 31547447 |
Johanna B Folk1,2, Laura M Tully3, Dawn M Blacker4, Brandi D Liles5, Khalima A Bolden6, Valerie Tryon7, Renata Botello8, Tara A Niendam9.
Abstract
Psychosis is conceptualized in a neurodevelopmental vulnerability-stress framework, and childhood trauma is one environmental factor that can lead to psychotic symptoms and the development of psychotic disorders. Higher rates of trauma are associated with higher psychosis risk and greater symptom frequency and severity, resulting in increased hospitalization rates and demand on outpatient primary care and mental health services. Despite an estimated 70% of individuals in the early stages of psychosis reporting a history of experiencing traumatic events, trauma effects (post-traumatic anxiety or depressive symptoms) are often overlooked in psychosis treatment and current interventions typically do not target commonly comorbid post-traumatic stress symptoms. We presented a protocol for Trauma-Integrated Cognitive Behavioral Therapy for Psychosis (TI-CBTp), an approach to treating post-traumatic stress symptoms in the context of early psychosis care. We provided a brief summary of TI-CBTp as implemented in the context of Coordinated Specialty Care and presented preliminary data supporting the use of TI-CBTp in early psychosis care. The preliminary results suggest that individuals with comorbid psychosis and post-traumatic stress symptoms can be appropriately and safely treated using TI-CBTp within Coordinated Specialty Care.Entities:
Keywords: cognitive behavioral therapy; coordinated specialty care; early psychosis; empirically supported treatment; trauma
Year: 2019 PMID: 31547447 PMCID: PMC6780072 DOI: 10.3390/jcm8091456
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241
Figure 1Integration of Cognitive-Behavioral Therapy for Psychosis and Empirically Supported Trauma Treatment within Coordinated Specialty Care: A Three-Stage Model. Note. CSC = Coordinated Specialty Care; This figure represents the three-stage approach to integrating Cognitive Behavioral Therapy for Psychosis and empirically supported trauma treatments within CSC. Key components of CSC are depicted in the outer circle as they should continue throughout the three stages. The three stages build upon one another, with each serving as a necessary foundation for subsequent stages.
Figure 2Decision tree to guide clinical approach. Note. APS = Attenuated positive symptoms; CPTp = Cognitive-behavioral therapy for psychosis; SCID = Structured Clinical Interview for DSM Disorders; PTSD = Post-traumatic stress disorder; TI-CBTp = Trauma-integrated cognitive-behavioral therapy for psychosis.
Baseline demographic characteristics.
| Stage 1 | Stage 2 | ||
|---|---|---|---|
| Age at assessment | Years | 19.1 (5.4) | 16.8 (4.9) |
| Sex | Female | 7 (58%) | 7 (70%) |
| Male | 5 (42%) | 3 (30%) | |
| Race | Black | 6(50%) | 4 (40%) |
| White | 2 (17%) | 2 (20%) | |
| Other Asian | 0 (0%) | 1 (10%) | |
| Other Pacific Islander | 1 (8%) | 0 (0%) | |
| Other Race | 3 (25%) | 3 (30%) | |
| Ethnicity | Other Hispanic/Latino | 4 (33%) | 3 (30%) |
| Not Hispanic | 8 (67%) | 7 (70%) | |
| Primary Language | English | 12 (100%) | 10 (100%) |
| Diagnosis | Mood with Psychotic Features | 5 (42%) | 3 (30%) |
| Schizophrenia Spectrum Disorders | 7 (58%) | 3 (30%) | |
| Other Specified/Not Otherwise Specified Schizophrenia Spectrum | 0 (0%) | 4 (40%) | |
| PTSD Diagnosis | PTSD Dx | 7 (58%) | 6 (60%) |
| Post-traumatic Stress Symptom Severity | Normalized Score | 62.3 (16.4) | 55.1 (23.5) |
| Psychosis Diagnosis | Recent Onset | 12 (100%) | 7 (70%) |
| Clinical High Risk | 0 (0%) | 3 (30%) | |
| Substance Use | Lifetime | 6 (50%) | 3 (30%) |
| Current | 5 (42%) | 2 (20%) | |
| Suicidal Ideation | Lifetime | 3.3 (2.0) | 2.2 (2.4) |
| Current | 1.0 (1.3) | 0.4 (1.0) | |
| Suicidal Behavior | Lifetime | 5 (42%) | 4 (40%) |
| Current | 0 (0%) | 1 (10%) | |
| Non-Suicidal Self-Injury | Lifetime | 5 (42%) | 4 (40%) |
| Current | 1 (8%) | 2 (20%) | |
| Insight | Current | 3.0 (1.1) | 2.0 (1.3) |
On the Clinical Global Impressions Scale, clients in both stages demonstrated clinically significant overall symptoms at baseline (Stage 1: M = 5.1; SD = 1.3; range = 2–7; Stage 2: M = 4.2; SD = 0.8; range = 3-5). Clients in the Stage 1 group demonstrated statistically higher levels of positive (U = 22.0, p = 0.019) and overall (U = 28.5, p= 0.049) symptoms compared to the Stage 2 group; there were no group differences in negative, depressive, mania, or cognitive symptoms. Clients also exhibited serious psychosocial impairments on the Global Assessment of Functioning (Stage 1 M = 32.3; SD = 13.3; Stage 2 M = 40.3, SD = 9.0), Global Functioning Role Scale (Stage 1 M = 4.3; SD = 2.6; Stage 2 M = 4.7, SD = 1.5), and Global Functioning Social Scale (Stage 1 M = 5.0; SD = 1.9; Stage 2 M = 5.4, SD = 0.9). Clients in the Stage 1 group had statistically significant lower Global Assessment of Functioning scores (t = −2.85, p = 0.011) than Stage 2 clients; social and role functioning did not significantly differ between the groups.
Figure 3Changes in outcomes across 12 months of treatment. Note. GAF = Global Assessment of Functioning; GFR = Global Functioning Role Scale; GFS = Global Functioning Social Scale; NSSIB = Non-suicidal self-injurious behavior. Stage 1 n = 12; Stage 2 n = 10. Ns differed by time point. For the overall, positive, depression, mania, and cognitive CGI data, the ns were as follows: Overall: Stage 1: 12 (baseline), 12 (6 months), 7 (12 months); Stage 2: 9 (baseline), 10 (6 months), 7 (12 months). For negative CGI scores: Stage 1: 12 (baseline), 11 (6 months), 7 (12 months); Stage 2: 9 (baseline), 9 (6 months), 7 (12 months).). For the functioning data, the ns were as follows: GAF: Stage 1: 12 (baseline), 12 (6 months), 7 (12 months); Stage 2: 10 (baseline), 10 (6 months), 7 (12 months). GFR: Stage 1: 12 (baseline), 11 (6 months), 7 (12 months); Stage 2: 9 (baseline), 10 (6 months), 7 (12 months). GFS: Stage 1: 12 (baseline), 11 (6 months), 6 (12 months); Stage 2: 9 (baseline), 10 (6 months), 7 (12 months). For Insight, ns were: Stage 1: 12 (baseline), 11 (6 months), 7 (12 months); Stage 2: 6 (baseline), 10 (6 months), 7 (12 months).
Figure 4Post-traumatic stress symptom severity at baseline (Stage 1: n = 6; Stage 2: n = 6) and 6-month follow-up (Stage 1: n = 2; Stage 2: n = 4). Post-traumatic stress symptoms were measured on the UCLA PTSD Reaction Index or the Child and Adolescent Trauma Screen (for minors), or the PTSD Checklist for DSM-5 (for adults). Scores were normalized to the maximum score for each respective measure.